Spots Global Cancer Trial Database for PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Official Title: Expression and Clinical Significance of PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Study ID: NCT03989297

Conditions

Nasopharyngeal Carcinoma

Interventions

Radiation

Study Description

Brief Summary: The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study the investigators investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients.

Detailed Description: NPC is a common type cancer in Macau and Southern China. The role of PD-L1 in NPC remains controversial. There many reasons behind these inconsistent findings. We used the SP263 antibody with the standard cut off value of 1% and 5%, which is frequently used for lung cancer and other cancer types. We also plan to include over 150 patients, which will be the largest study in NPC. This will help us to gain insights in NPC.